StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Ayala Pharmaceuticals stock opened at $0.03 on Thursday. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49. The business’s fifty day moving average is $0.04 and its 200 day moving average is $0.09. The stock has a market capitalization of $1.15 million, a PE ratio of 0.00 and a beta of 1.70.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.